BiotechTube

Idebenone 150 mg film-coated tablets + placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy (DMD)

Conditions

Duchenne Muscular Dystrophy (DMD)

Trial Timeline

Sep 1, 2016 → Dec 1, 2020

NCT ID
NCT02814019

About Idebenone 150 mg film-coated tablets + placebo

Idebenone 150 mg film-coated tablets + placebo is a phase 3 stage product being developed by Santhera Pharmaceuticals for Duchenne Muscular Dystrophy (DMD). The current trial status is terminated. This product is registered under clinical trial identifier NCT02814019. Target conditions include Duchenne Muscular Dystrophy (DMD).

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02814019Phase 3Terminated

Competing Products

20 competing products in Duchenne Muscular Dystrophy (DMD)

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
41
NS-089/NCNP-02Nippon ShinyakuPhase 2
52
ViltolarsenNippon ShinyakuPhase 3
77
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
41
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
52
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
52
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
52

Other Products from Santhera Pharmaceuticals

vamorolone 40 mg/mL oral suspensionApproved
77
IdebenoneApproved
77
Placebo + IdebenonePhase 3
69
idebenonePhase 3
69
idebenone + PlaceboPhase 3
69